An experimental Klebsiella pneumoniae pneumonia in rats was used to study the effect of protein binding of cefoxitin and cefazolin on their therapeutic activity. Both cephalosporins were similar with respect to their antimicrobial activity against the K. pneumoniae in vitro, but they differed in their degree of protein binding, being 34% for cefoxitin and 89 to 93% for cefazolin in uninfected rats and 24 and 71 to 83%, respectively, in infected rats. Various doses of these agents were administered by continuous infusion, which started 5 h after bacterial inoculation and continued for 65 h. Antimicrobial response was evaluated with respect to the numbers of bacteria recovered from lung and blood at the end of treatment. An inhibitory effect of protein binding on the in vivo antimicrobial activity was demonstrated. Cefoxitin was therapeutically effective at a constant plasma level that reached the MIC. To obtain a similar effect with cefazolin the plasma level of that drug had to be increased to a concentration more than three times the MIC.
Binding of antimicrobial agents to serum proteins and tissues affects their distribution, elimination rate, and microbiological activity (10, 22, 24, 32, 33) . Only the free, unbound fraction can pass into the extravascular compartment or be excreted by the kidneys. Protein-bound antibiotic has no antibacterial activity. In spite of extensive coverage of this subject in the literature, the clinical significance of this phenomenon is still controversial. The effect of serum protein binding on the rate at which antibiotics diffuse out from the vascular compartment into the tissues has been studied in various animal and human models. Results of some of these studies show that penetration into tissues and extravascular fluid is primarily dependent on the fraction of free, unbound antibiotic in plasma (4, 5, 30, 33, 34) , whereas others show the contrary (7, 15, 21, 29, 31) . The actual concentration of active antibiotic at the site of infection is also determined by tissue binding and the severity of the infection (6, 10, 14) . Binding varies from tissue to tissue. In severe infections with hypoalbuminemia the percentage of unbound antibiotic in serum is increased (8, 28) . There has been limited experimental work on the relevance of protein binding of antibiotics to therapeutic efficacy (17) (18) (19) 25) . As will be discussed below, these studies have also yielded somewhat contradictory results.
In the work reported here, we compared the therapeutic activity of cefoxitin and cefazolin in rats with experimental pneumonia induced by Klebsiella pneumoniae. Both cephalosporins are similar with respect to their microbiological activity against K. pneumoniae in vitro but differ in their degree of protein binding in uninfected and infected rats. Because the half-life of the antibiotic in plasma may be as important as the protein binding in determining the degree of extravascular tissue distribution, the cephalosporins were administered in various doses by way of continuous infusion. * [1] [2] [3] [4] 1983) .
Pneumonia. Experimental pneumonia was produced as described previously (2) . In brief, rats were anesthetized with Hypnorm (Duphar B.V., Amsterdam, The Netherlands) and pentobarbital (Abbott Laboratories, North Chicago, Ill.). The left main stem bronchus was intubated, and the left lobe of the lung was inoculated with 0.02 ml of a saline suspension of K. pneumoniae containing 8 x 104 (6 x 104 to 10 x 104) CFU (27) , was used. In brief, 6 weeks prior to its use a tissue cage constructed from perforated Teflon (length, 40 mm; outer diameter, 7 mm; inner diameter, 5 mm; 30% perforation) connected with 50 mm of polyethylene tube was implanted subcutaneously. Rats were anesthetized prior to treatment with antibiotics. The distal portion of the polyethylene tube was recovered via an incision in the neck of the animal and connected with a polyethylene tube and a swivel to a 12 ml syringe. This syringe was placed on a Varifusor pump (Breda Scientific, Breda, The Netherlands). The cephalosporin at the required concentration was infused at a constant rate of 0.116 ml/h. By this technique prolonged steady-state levels were reached within 3 h after the start of the infusion.
Therapeutic results. Response to antimicrobial treatment was evaluated with respect to the numbers of bacteria in the lung (left lobe) and in blood and pleural fluid at the time of sacrifice of the rats, i.e., 70 h after bacterial inoculation. Samples of blood and pleural fluid were obtained for culture. Pleural exudate was obtained by washing the chest cavity with physiological saline (0.5 ml). After macroscopic examination, the left lung was removed and homogenized in 20 ml of physiological saline containing beta-lactamase (VirTis homogenizer; 30 s at 10,000 rpm). Serial 10-fold dilutions of homogenates and blood in saline were prepared, and 0.2-ml volumes of each dilution were spread on blood agar plates. The numbers of viable organisms in the residual homogenate of the left lung were measured by the pour-plate method.
Statistics. The Wilcoxon rank-sum test was used to estimate whether results of quantitative cultures of the left lung in antibiotic-treated rats or untreated rats differed significantly from each other.
Measurement of antibiotic concentrations in serum. Blood specimens were taken from the heart of noninfected and infected rats, and serum was separated. Cefoxitin or cefazolin in serum was measured via a modified high-pressure liquid chromatographic method (2) . We used the highpressure liquid chromatographic method because standard curves cannot be prepared in fluid with protein concentrations equal to those of the unknown samples of antibiotictreated, infected rats (23 (Fig. 1) . The protein binding for both drugs in the medium was 0.2 and 0.6% for cefoxitin and cefazolin, respectively. Neither cephalosporin was inactivated by beta-lactamases produced by K. pneumoniae. Rat serum, at concentrations of 50 or 90%, had no effect on the killing of K. pneumoniae by 6.4 ,ug of cefoxitin per ml (Fig.  2) . The killing of K. pneumoniae by 6.4 p.g of cefazolin per ml was inhibited by rat serum during the first 2 h of incubation (Fig. 3) ; from that time bacterial killing was observed in the presence of 50% rat serum, whereas bacterial growth was observed in the presence of 90% rat serum. Rat serum did not affect bacterial growth in broth without antibiotic.
Pharmacokinetic properties of cefoxitin and cefazolin in normal and infected rats. The serum concentrations of the cephalosporins at the treatment doses used and the percentages of serum protein binding for both cephalosporins are shown in Fig. 4 with the values for uninfected rats, which had albumin concentrations in serum of 36.3 ± 0.38 mg/ml. As a result of infection, body clearance of total drug was unchanged for cefazolin and slightly decreased for cefoxitin; however, clearance of free drug was significantly decreased (P < 0.05) to 58 and 42% for cefoxitin and cefazolin, respectively (Table 1) .
Therapeutic efficacy of cefoxitin and cefazolin in experimental pneumonia. Responses of K. pneumoniae pneumonia to cephalosporin treatment are summarized in Table 2 . Therapy was started S h after bacterial inoculation and continued for 65 h. At 5 h after inoculation (group F) the numbers of CFU in the left lung of untreated rats had increased up to sevenfold; a median number of S x 105 was cultured from the left lung; blood and pleural fluid were sterile. At 70 h (group E) a median number of 1010 CFU was cultured from the left lung; all rats had bacteria in the blood and pleural fluid. A steady-state total serum concentration of cefoxitin at the MIC and MBC level (group A) resulted in decreased numbers of bacteria cultured from the left lung, which was significantly different from that of untreated controls (P = 0.0003). A median number of 4 x 104 CFU was cultured from the left lung. Only 1 of 10 rats had bacteria in the blood. Cefazolin at a continuous total serum concentration at the MIC and MBC level (group B) did not result in a therapeutic effect. Numbers of bacteria in lung, blood, and pleural fluid were not significantly different (P = 0.199) from those in untreated rats. In addition, the numbers of bacteria in the lungs of these cefazolin-treated rats were significantly different (P = 0.0002) from those treated with cefoxitin (group A). With an increase in the cefazolin dose, producing a total serum concentration of 5.69 pug/ml (group C), the numbers of bacteria in the lung were slightly decreased but still significantly different (P = 0.005) from those in the cefoxitintreated rats (group A). Treatment of rats with cefazolin at a total level of 11.53 ,ug/ml in serum (group D) produced a (4, 5, 7, 15, 21, 29, 30, 31, 33, 34) . The discrepancies may be explained by differences in the mode and duration of antibiotic administration as shown by Peterson and co-workers, who compared continuous infusions and single-dose treatments (12, 21, 22, 29) . In addition they demonstrated that the extent of binding in the extravascular fluid is also an important factor (21) . Antibiotics vary in the capacity to bind to different types of tissues and with the degree and severity of infection (6, 9, 10, 14) . Moreover hypoalbuminemia associated with severe infections may account for an increase of the percentage of unbound drug (8, 28) . Therefore, estimation of concentrations of biologically active antibiotic in the tissues is complicated. The relevance of protein binding of antibiotics to therapeutic efficacy can only be established in experimental infections. For that reason, we studied the effect of protein binding on the therapeutic efficacy of cefoxitin and cefazolin in K. pneumoniae pneumonia in rats. Neither cephalosporin was susceptible to beta-lactamases of K. pneumoniae. The antibacterial activity of both nonprotein-bound cephalosporins against K. pneumoniae in vitro was similar at the concentrations tested. An inhibitory effect of serum protein binding on the in vitro killing of the K. pneumoniae strain was demonstrated for the highly proteinbound cefazolin, but was not observed for cefoxitin with low protein binding. No microbiologically active metabolites were recovered, which is in accordance with other reports (1, 20, 26) . However, the protein binding of the cephalospo- (18) in mice with intraperitoneal Staphylococcuts auireius infection, in which isoxazolylpenicillins of similar activity and pharmacology were compared. Therapeutic activity was diminished as a result of protein binding. This finding was also confirmed by Muckter et al. (19) in similar studies with ciclacillin and dicloxacillin. However, in renal infections caused by S. aureuis in mice, Mattie et al. (17) have demonstrated that the therapeutic effect of nafcillin was superior to that of cloxacillin, which is in contrast with what one would expect on the basis of the protein binding. The difference in efficacy was only observed 18 h after the last antibiotic injection. The conclusion derived from this study should be considered with caution because the model of infection in the renal medulla might not be appropriate for this purpose. Our results differ from those of Sande et al. (16) , who have shown that the therapeutic activity of cephalosporins against Streptoco(ccus pneutmoniae meningitis in rabbits is not directly related to low protein binding.
